These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 10624770)

  • 1. Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer.
    Bury T; Corhay JL; Duysinx B; Daenen F; Ghaye B; Barthelemy N; Rigo P; Bartsch P
    Eur Respir J; 1999 Dec; 14(6):1376-80. PubMed ID: 10624770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-fluorodeoxyglucose positron emission tomography/computed tomography is useful in postoperative follow-up of asymptomatic non-small-cell lung cancer patients.
    Toba H; Sakiyama S; Otsuka H; Kawakami Y; Takizawa H; Kenzaki K; Kondo K; Tangoku A
    Interact Cardiovasc Thorac Surg; 2012 Nov; 15(5):859-64. PubMed ID: 22914804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Value of positron emission tomography with 18-fluorodeoxyglucose (FDG-PET) in diagnosis of recurrent bronchial carcinoma].
    Ukena D; Hellwig D; Palm I; Rentz K; Leutz M; Hellwig AP; Kirsch CM; Sybrecht GW
    Pneumologie; 2000 Feb; 54(2):49-53. PubMed ID: 10731756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of positron emission tomography for lung cancer staging.
    Albes JM; Dohmen BM; Schott U; Schülen E; Wehrmann M; Ziemer G
    Eur J Surg Oncol; 2002 Feb; 28(1):55-62. PubMed ID: 11869015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma.
    Poncelet AJ; Lonneux M; Coche E; Weynand B; Noirhomme P;
    Eur J Cardiothorac Surg; 2001 Sep; 20(3):468-74; discussion 474-5. PubMed ID: 11509265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study.
    Kalff V; Hicks RJ; MacManus MP; Binns DS; McKenzie AF; Ware RE; Hogg A; Ball DL
    J Clin Oncol; 2001 Jan; 19(1):111-8. PubMed ID: 11134203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer.
    Berlangieri SU; Scott AM; Knight SR; Fitt GJ; Hennessy OF; Tochon-Danguy HJ; Clarke CP; McKay WJ
    Eur J Cardiothorac Surg; 1999 Sep; 16 Suppl 1():S25-30. PubMed ID: 10536941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Significance of FDG Uptake of Bone Marrow on PET/CT in Patients With Non-Small-Cell Lung Cancer After Curative Surgical Resection.
    Lee JW; Na JO; Kang DY; Lee SY; Lee SM
    Clin Lung Cancer; 2017 Mar; 18(2):198-206. PubMed ID: 27495385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial.
    Darling GE; Maziak DE; Inculet RI; Gulenchyn KY; Driedger AA; Ung YC; Gu CS; Kuruvilla MS; Cline KJ; Julian JA; Evans WK; Levine MN
    J Thorac Oncol; 2011 Aug; 6(8):1367-72. PubMed ID: 21587082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer.
    Hellwig D; Gröschel A; Graeter TP; Hellwig AP; Nestle U; Schäfers HJ; Sybrecht GW; Kirsch CM
    Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):13-21. PubMed ID: 16151765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of 18F-FDG PET/CT in the treatment of patients with non-small cell lung cancer.
    Taus Á; Aguiló R; Curull V; Suárez-Piñera M; Rodríguez-Fuster A; Rodríguez de Dios N; Pijuan L; Zuccarino F; Vollmer I; Sánchez-Font A; Belda-Sanchis J; Arriola E
    Arch Bronconeumol; 2014 Mar; 50(3):99-104. PubMed ID: 24360985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management.
    Keidar Z; Haim N; Guralnik L; Wollner M; Bar-Shalom R; Ben-Nun A; Israel O
    J Nucl Med; 2004 Oct; 45(10):1640-6. PubMed ID: 15471827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis of recurrence and follow-up using FDG-PET/CT for postoperative non-small-cell lung cancer patients.
    Toba H; Kawakita N; Takashima M; Matsumoto D; Takizawa H; Otsuka H; Tangoku A
    Gen Thorac Cardiovasc Surg; 2021 Feb; 69(2):311-317. PubMed ID: 32909168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved radiologic staging of lung cancer with 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography and computed tomography registration.
    Aquino SL; Asmuth JC; Alpert NM; Halpern EF; Fischman AJ
    J Comput Assist Tomogr; 2003; 27(4):479-84. PubMed ID: 12886128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: a prospective analysis of 50 cases. Leuven Lung Cancer Group.
    Vansteenkiste JF; Stroobants SG; De Leyn PR; Dupont PJ; Verschakelen JA; Nackaerts KL; Mortelmans LA
    Chest; 1997 Dec; 112(6):1480-6. PubMed ID: 9404742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Staging of head and neck tumors: [18F]fluorodeoxyglucose positron emission tomography compared with physical examination and conventional imaging modalities.
    Sigg MB; Steinert H; Grätz K; Hugenin P; Stoeckli S; Eyrich GK
    J Oral Maxillofac Surg; 2003 Sep; 61(9):1022-9. PubMed ID: 12966477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Value of 18F-fluorodeoxyglucose positron emission tomography imaging in staging of non-small cell lung cancer].
    Guan Y; He S; Dong J
    Zhonghua Yi Xue Za Zhi; 2001 Oct; 81(19):1180-3. PubMed ID: 11769705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative impact of standard approach, FDG PET and FDG dual-head coincidence gamma camera imaging in preoperative staging of patients with non-small-cell lung cancer.
    Delahaye N; Crestani B; Rakotonirina H; Lebtahi R; Sarda L; Girard P; Charpentier E; Fery-Lemonnier E; Syrota A; Aubier M; Le Guludec D
    Nucl Med Commun; 2003 Dec; 24(12):1215-24. PubMed ID: 14627847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.